Zenas BioPharma (NASDAQ:ZBIO) Receives “Buy” Rating from Guggenheim

Posted by Brian Himes on Aug 14th, 2026

Zenas BioPharma (NASDAQ:ZBIO – Get Free Report)‘s stock had its “buy” rating reissued by Guggenheim in a research report issued on Friday,Benzinga reports. They presently have a $55.00 price objective on the stock. Guggenheim’s price target would suggest a potential upside of 88.58% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Weiss Ratings downgraded Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. Morgan Stanley increased their target price on Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Finally, Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $44.29.

View Our Latest Research Report on Zenas BioPharma

Zenas BioPharma Stock Performance

Shares of ZBIO opened at $29.16 on Friday. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -3.42 and a beta of -1.03. The business’s fifty day simple moving average is $26.71 and its two-hundred day simple moving average is $23.34. Zenas BioPharma has a 12 month low of $13.50 and a 12 month high of $44.60. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04.

Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The firm had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $15.00 million. Research analysts anticipate that Zenas BioPharma will post -4.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Leon O. Moulder, Jr. purchased 60,000 shares of the stock in a transaction on Monday, May 18th. The shares were acquired at an average price of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the acquisition, the chief executive officer directly owned 96,928 shares of the company’s stock, valued at $1,636,144.64. This trade represents a 162.48% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 22.00% of the company’s stock.

Institutional Trading of Zenas BioPharma

Several institutional investors and hedge funds have recently modified their holdings of the company. SR One Capital Management LP lifted its stake in shares of Zenas BioPharma by 2.6% during the 4th quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock valued at $182,924,000 after buying an additional 126,315 shares in the last quarter. NEA Management Company LLC increased its stake in Zenas BioPharma by 28.9% in the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock worth $127,928,000 after buying an additional 789,500 shares in the last quarter. Federated Hermes Inc. increased its stake in Zenas BioPharma by 45.9% in the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock worth $98,603,000 after buying an additional 853,740 shares in the last quarter. BlackRock Inc. bought a new stake in Zenas BioPharma during the second quarter valued at about $68,176,000. Finally, Vanguard Group Inc. lifted its position in shares of Zenas BioPharma by 25.0% in the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after acquiring an additional 290,307 shares in the last quarter.

Zenas BioPharma Company Profile

(Get Free Report)

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.